Press Releases for AMLN

Press Releases
The Fortune Financial Undertakes Review of Stocks in the Healthcare and Services Sectors
Asterand Announces Agreement to Acquire BioSeek
FDA: Byetta drug label is revised
Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
Amylin Pharmaceuticals Reports Second Quarter Financial Results
Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
Amylin Pharmaceuticals to Webcast Second Quarter Results
Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
Interim Study Results Presented at ADA 2009: Exenatide Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs
Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009
Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
Amylin Announces Preliminary Tabulation of Annual Meeting Results
Amylin Pharmaceuticals to Present Compelling Efficacy and Safety Data From Diabetes Programs at ADA 2009
Amylin Announces Preliminary Results of Annual Meeting of Stockholders
Eastbourne Comments on Election of Directors at Amylin Annual Meeting of Shareholders
Amylin Advises All Shareholders to Vote Their Blue Proxy Card Today
Eastbourne Calls on All Amylin Shareholders to Vote Today and Support Change to the Amylin Board of Directors
Eastbourne Calls on Amylin Employees to Help Shape the Company’s Future and Support Change to the Board
Alkermes Reports Financial Results for Fiscal 2009 and Provides Financial Expectations for Fiscal 2010
Fourth Independent Proxy Advisory Firm Recommends Change to Board of Directors at Amylin Pharmaceuticals
Amylin Responds to Eastbourne Letter
Eastbourne Sends Letter to Amylin Board
Three Independent Proxy Advisory Firms Support Stockholder Nominees in Amylin Proxy Fight
Eastbourne Capital Sends Letter to Amylin Shareholders Outlining Broad Call for Change to Amylin Board
Three Leading Independent Proxy Advisory Firms Now Support Change at Amylin Pharmaceuticals
Amylin Comments on RiskMetrics Report
Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
Lilly Reports Strong First-Quarter 2009 Results - Apr 20 2009 12:57PM
Lilly Reports Strong First-Quarter 2009 Results - Apr 20 2009 6:55AM
Amylin Pharmaceuticals Reports First Quarter Financial Results - Apr 17 2009 2:00PM
Amylin Pharmaceuticals to Webcast First Quarter Results - Apr 9 2009 4:43PM
Eastbourne Capital Sends Letter to Amylin Pharmaceuticals Board of Directors
Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
Eastbourne Capital Comments on Amylin Pharmaceuticals Lawsuit in Delaware and Recent Developments in Effort to Enjoin Company’s “Poison Puts”
Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
WallStSense.Com Initiates Free Ratings Report on PBCT, AMLN, ALKS and ATHR... Sign Up Now
Beacon Equity Issues Technical Trade Alerts on Market Movers: AMLN, MPEL, ANAD, TBSI, NUVA, ITRI
Eastbourne Capital Management Comments on Delaware Lawsuit to Enjoin Amylin Pharmaceuticals “Poison Puts”
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Zacks Analyst Blog Highlights: Vivo Participacoes, America Movil, TIM Participacoes, Amylin Pharmaceuticals, Inc. And Eli Lilly.
Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
Eastbourne Capital Management Sends Letter to Amylin Pharmaceuticals Board of Directors
Eastbourne Capital Management Nominates Five Directors for Amylin Pharmaceuticals Board
Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
Amylin Pharmaceuticals Comments on Shareholder 13-D Filing
BenchmarkJournal.Com (Complimentary) Analyst Review for and AMZN, AMLN, FLEX and ANPI
Amylin Pharmaceuticals Reports 2008 Financial Results
Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
Amylin Pharmaceuticals to Webcast Year-End Results
Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Zacks Analyst Blog Highlights: Royal Dutch Shell, Plc, Amylin Pharmaceuticals Inc., Eli Lilly, OSI Pharmaceuticals, Inc., And NCI Building Systems Inc.
Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
Zacks Analyst Blog Highlights: Schlumberger Ltd., Amylin Pharmaceuticals, Inc., Eli Lilly & Co., Onyx Pharmaceuticals, Inc. And Diageo Plc.
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
Amylin Pharmaceuticals to Webcast Third Quarter Results
Zacks Analyst Blog Highlights: Epicor Software Corp., Amylin Pharmaceuticals, Inc., CNOOC Ltd., Skyworks Solutions, Inc. And Nokia Corp. - Oct 6 2008 4:17PM
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
First Reported Head-to-Head Study Showed BYETTA(R) (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia(TM) (sitagliptin) in Patients With Type 2 Diabetes
BeaconEquity.com Issues Technical Trade Alerts on BioPharmaceutical Stocks: CEGE, AMLN, DNA, GENZ, AMGN, GILD
Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
Amylin and Lilly Set Date and Time for Conference Call
Lilly and Amylin Set Date and Time for Conference Call
Amylin Pharmaceuticals Reports Second Quarter Financial Results
Amylin Pharmaceuticals to Webcast Second Quarter Results
After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin
Seven Summits Research Releases Comments on MCD, NUE, NEM, CF, and AMLN
Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
Amylin Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
New Analyst Reports for OSI PHARMACEUTICALS INC, CITRIX SYSTEMS INC, AMYLIN PHARMACEUTICALS INC, and IMCLONE SYSTEMS INCORPORATED
Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders - May 26 2008 10:33PM
Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference - May 26 2008 10:31PM
Amylin Pharmaceuticals to Present at Baird Growth Stock Conference - Jun 1 2008 7:07AM
Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference - Jun 1 2008 7:06AM
Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity - Jun 1 2008 7:06AM
Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
BellwetherReport.com Initiates Analyst Coverage on GFIG, PKTR, AMLN and CNR
Amylin Pharmaceuticals Reports First Quarter Financial Results - Jun 1 2008 7:05AM
Amylin Pharmaceuticals to Webcast First Quarter Results - Jun 1 2008 7:05AM